The host-tumor interface in B-cell non-Hodgkin lymphoma: A new world to investigate

Current Hematologic Malignancy Reports

Volumn 4, Issue 4, 2009, Pages 196-201

  Rachinel, Nicolas ^a   Salles, Gilles ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; EPHRIN RECEPTOR A1; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; PROTEIN BCL 2; SMAD1 PROTEIN; SONIC HEDGEHOG PROTEIN; STAT1 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; B CELL LYMPHOMA; CARCINOGENESIS; CELL INTERACTION; DENDRITIC CELL; DISEASE ACTIVITY; GENE EXPRESSION REGULATION; GERMINAL CENTER; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LYMPHOCYTE MIGRATION; LYMPHOID ORGAN; MACROPHAGE; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; STROMA CELL; T LYMPHOCYTE SUBPOPULATION;

ANTINEOPLASTIC AGENTS; BYSTANDER EFFECT; CELL COMMUNICATION; CHEMOKINES; CYTOKINES; DISEASE PROGRESSION; HUMANS; LYMPHOID TISSUE; LYMPHOMA, B-CELL;

EID: 70349756957     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-009-0026-1     Document Type: Review

References (43)

1. Dave SS, Wright G, Tan B, et al.: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351: 2159-2169.
2. Lenz G, Wright G, Dave SS, et al.: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359: 2313-2323.
3. Kim MY, McConnell FM, Gaspal FM, et al.: Function of CD4+CD3-cells in relation to B- and T-zone stroma in spleen. Blood 2007, 109: 1602-1610.
4. Ngo VN, Cornall RJ, Cyster JG: Splenic T zone development is B cell dependent. J Exp Med 2001, 194: 1649-1660.
5. Murakami T, Chen X, Hase K, et al.: Splenic CD19-CD35+B220+ cells function as an inducer of follicular dendritic cell network formation. Blood 2007, 110: 1215-1224.
6. Katakai T, Hara T, Sugai M, et al.: Lymph node fibroblastic reticular cells construct the stromal reticulum via contact with lymphocytes. J Exp Med 2004, 200: 783-795.
7. Jundt F, Probsting KS, Anagnostopoulos I, et al.: Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004, 103: 3511-3515.
8. Calvo KR, Dabir B, Kovach A, et al.: IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. Blood 2008, 112: 3818-3826.
9. Dierks C, Grbic J, Zirlik K, et al.: Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007, 13: 944-951.
10. Farinha P, Masoudi H, Skinnider BF, et al.: Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005, 106: 2169-2174.
11. Alvaro T, Lejeune M, Salvado MT, et al.: Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006, 24: 5350-5357.
12. Canioni D, Salles G, Mounier N, et al.: High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008, 26: 440-446.
13. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, et al.: A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristineprednisone. Clin Cancer Res 2007, 13: 5784-5789.
14. Byers RJ, Sakhinia E, Joseph P, et al.: Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood 2008, 111: 4764-4770.
15. Carbonnelle-Puscian A, Copie-Bergman C, Baia M, et al.: The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages. Leukemia 2009, 23: 952-960.
16. Harjunpaa A, Taskinen M, Nykter M, et al.: Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br J Haematol 2006, 135: 33-42.
17. Marmey B, Boix C, Barbaroux JB, et al.: CD14 and CD169 expression in human lymph nodes and spleen: Specific expansion of CD14+ CD169-monocyte-derived cells in diffuse large B-cell lymphomas. Hum Pathol 2006, 37: 68-77.
18. Manconi R, Poletti A, Volpe R, et al.: Dendritic reticulum cell pattern as a microenvironmental indicator for a distinct origin of lymphoma of follicular mantle cells. Br J Haematol 1988, 68: 213-218.
19. Carbone A, Gloghini A, Gruss HJ, Pinto A: CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 1995, 147: 912-922.
20. Liu YJ, Malisan F, de Bouteiller O, et al.: Within germinal centers, isotype switching of immunoglobulin genes occurs after the onset of somatic mutation. Immunity 1996, 4: 241-250.
21. Manz RA, Hauser AE, Hiepe F, Radbruch A: Maintenance of serum antibody levels. Annu Rev Immunol 2005, 23: 367-386.
22. Travert M, Ame-Thomas P, Pangault C, et al.: CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol 2008, 181: 1001-1011.
23. Eeva J, Postila V, Matto M, et al.: Kinetics and signaling requirements of CD40-mediated protection from B cell receptor-induced apoptosis. Eur J Immunol 2003, 33: 2783-2791.
24. Homig-Holzel C, Hojer C, Rastelli J, et al.: Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med 2008, 205: 1317-1329.
25. Fanale MA, Younes A: Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007, 67: 333-350.
26. Horna P, Cuenca A, Cheng F, et al.: In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood 2006, 107: 2871-2878.
27. Plumas J, Jacob MC, Chaperot L, et al.: Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998, 91: 2875-2885.
28. Yang ZZ, Novak AJ, Ziesmer SC, et al.: Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2006, 66: 10145-10152.
29. Yang ZZ, Novak AJ, Ziesmer SC, et al.: CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. Blood 2007, 110: 2537-2544.
30. Mittal S, Marshall NA, Duncan L, et al.: Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008, 111: 5359-5370.
31. Bettelli E, Carrier Y, Gao W, et al.: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441: 235-238.
32. Yang ZZ, Novak AJ, Ziesmer SC, et al.: Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2009, 69: 5522-5530.
33. Carreras J, Lopez-Guillermo A, Fox BC, et al.: High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006, 108: 2957-2964.
34. Lee AM, Clear AJ, Calaminici M, et al.: Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006, 24: 5052-5059.
35. Curiel TJ, Coukos G, Zou L, et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10: 942-949.
36. Wahlin BE, Sander B, Christensson B, Kimby E: CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007, 13: 388-397.
37. Carreras J, Lopez-Guillermo A, Roncador G, et al.: High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009, 27: 1470-1476.
38. Fiore F, Von Bergwelt-Baildon MS, Drebber U, et al.: Dendritic cells are significantly reduced in non-Hodgkin's lymphoma and express less CCR7 and CD62L. Leuk Lymphoma 2006, 47: 613-622.
39. Kurtova AV, Tamayo AT, Ford RJ, Burger JA: Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): Importance for interactions with the stromal microenvironment and specific targeting. Blood 2009, 113: 4604-4613.
40. Bajenoff M, Egen JG, Koo LY, et al.: Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. Immunity 2006, 25: 989-1001.
41. Husson H, Freedman AS, Cardoso AA, et al.: CXCL13 (BCA-1) is produced by follicular lymphoma cells: Role in the accumulation of malignant B cells. Br J Haematol 2002, 119: 492-495.
42. Roulland S, Navarro JM, Grenot P, et al.: Follicular lymphoma-like B cells in healthy individuals: A novel intermediate step in early lymphomagenesis. J Exp Med 2006, 203: 2425-2431.
43. de Jong D, Rosenwald A, Chhanabhai M, et al.: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007, 25: 805-812.